Vimectanin DUO 50 mg/ml + 1 mg/ml oral suspension for sheep
Vimectanin DUO 50 mg/ml + 1 mg/ml oral suspension for sheep
Authorised
- Triclabendazole
- Ivermectin
Product identification
Medicine name:
Vimectanin DUO 50 mg/ml + 1 mg/ml oral suspension for sheep
VIMECTANIN DUO 50 MG/ML + 1 MG/ML SUSPENSION BUVABLE POUR OVINS
Active substance:
- Triclabendazole
- Ivermectin
Target species:
-
Sheep (lamb)
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Triclabendazole50.00/milligram(s)1.00millilitre(s)
-
Ivermectin1.00/milligram(s)1.00millilitre(s)
Pharmaceutical form:
-
Oral suspension
Withdrawal period by route of administration:
-
Oral use
-
Sheep (lamb)
-
Meat and offal27day
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QP54AA51
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
France
Package description:
- 1 litre PE bottle
- 5 litre PE bottle
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Generic application (Article 18 of Regulation (EU) 2019/6)
Marketing authorisation holder:
- Pharma VIM Kft.
Marketing authorisation date:
Manufacturing sites for batch release:
- Vim Spectrum S.R.L.
Responsible authority:
- French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
- FR/V/5490693 8/2024
Date of authorisation status change:
Reference member state:
-
Hungary
Procedure number:
- HU/V/0151/001
Concerned member states:
-
France
-
Greece
-
Ireland
-
Italy
-
Romania
-
Spain
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Package Leaflet and Labelling
This document does not exist in this language (English). You can find it
in another language below.
French (PDF)
Published on: 24/06/2025
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
French (PDF)
Published on: 24/06/2025